Skip to main content

Advertisement

Reviews

Section edited by Sandra Demaria, MD and Thomas F. Gajewski, MD, PhD

Reviews are generally directly commissioned by JITC editors. These are fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Topics include recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next written by authors who are leading contributors in the field. We do not encourage unsolicited submissions for this type of article. However, potential authors may send presubmission enquiries addressed to the section editors at JITCEditor@sitcancer.org for further consideration by JITC editorial leadership.

Page 1 of 2

  1. Hepatocellular carcinoma (HCC) is the second deadliest cancer worldwide, due to its high incidence and poor prognosis. Frequent initial presentation at advanced stages along with impaired liver function limit ...

    Authors: Marc Hilmi, Cindy Neuzillet, Julien Calderaro, Fouad Lafdil, Jean-Michel Pawlotsky and Benoit Rousseau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:333

    Content type: Review

    Published on:

  2. The immunologic landscape of the host and tumor play key roles in determining how patients will benefit from immunotherapy, and a better understanding of these factors could help inform how well a tumor respon...

    Authors: Andrew B. Nixon, Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang and Catherine Fleener

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:325

    Content type: Review

    Published on:

  3. The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset of patients, mos...

    Authors: Andrew A. Davis and Vaibhav G. Patel

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:278

    Content type: Short report

    Published on:

  4. Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the p...

    Authors: Bridget P. Keenan, Lawrence Fong and Robin K. Kelley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:267

    Content type: Review

    Published on:

  5. The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now ...

    Authors: Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg and Eric Vivier

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:263

    Content type: Review

    Published on:

  6. Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its...

    Authors: Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini, Giovanni Martinelli and Ugo De Giorgi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:258

    Content type: Review

    Published on:

  7. Immune checkpoint inhibitors (ICBs) have revolutionized cancer treatment producing remarkable and durable responses for a range of malignancies. However, the additional modulation of immune response by ICBs ma...

    Authors: Amalia Anastasopoulou, Dimitrios C. Ziogas, Michael Samarkos, John M. Kirkwood and Helen Gogas

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:239

    Content type: Review

    Published on:

  8. Dendritic cells (DCs) are central players in the immune system, with an exquisite capacity to initiate and modulate immune responses. These functional characteristics have led to intense research on the develo...

    Authors: João Calmeiro, Mylène Carrascal, Célia Gomes, Amílcar Falcão, Maria Teresa Cruz and Bruno Miguel Neves

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:238

    Content type: Review

    Published on:

  9. Immunotherapy has led to a paradigm shift in the treatment of many advanced malignancies. Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and melanoma, checkpoint inhibition-...

    Authors: Arsen Osipov, May Tun Saung, Lei Zheng and Adrian G. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:224

    Content type: Review

    Published on:

  10. Management of small cell lung cancer (SCLC) has not changed over the last decades. In more recent years, alterations of DNA repair machinery and other molecular pathways have been identified in SCLC and precli...

    Authors: A. Pavan, I. Attili, G. Pasello, V. Guarneri, P. F. Conte and L. Bonanno

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:205

    Content type: Review

    Published on:

  11. Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is emerging as a promising biomarker for immunotherapy response in cancer patients. TMB can be quantitated by a number of...

    Authors: Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci and Luca Mazzarella

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:183

    Content type: Review

    Published on:

  12. Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial d...

    Authors: Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M. Coussens, Daniel D. De Carvalho, David G. DeNardo, Jérôme Galon, Howard L. Kaufman…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:131

    Content type: Review

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:167

  13. Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administer...

    Authors: Kalijn F. Bol, Gerty Schreibelt, Katrin Rabold, Stefanie K. Wculek, Julia Katharina Schwarze, Andrzej Dzionek, Alvaro Teijeira, Lana E. Kandalaft, Pedro Romero, George Coukos, Bart Neyns, David Sancho, Ignacio Melero and I. Jolanda M. de Vries

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:109

    Content type: Review

    Published on:

  14. The activity of the commensal microbiota significantly impacts human health and has been linked to the development of many diseases, including cancer. Gnotobiotic animal models have shown that the microbiota h...

    Authors: Jessica Fessler, Vyara Matson and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:108

    Content type: Review

    Published on:

  15. The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and chimeric antigen receptor [CAR]-T cells), is raising ...

    Authors: Jasmine Davda, Paul Declerck, Siwen Hu-Lieskovan, Timothy P. Hickling, Ira A. Jacobs, Jeffrey Chou, Shahram Salek-Ardakani and Eugenia Kraynov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:105

    Content type: Review

    Published on:

  16. Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, an...

    Authors: Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, Valentina Guarneri and Aleix Prat

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:90

    Content type: Review

    Published on:

  17. Quantitative lymphocyte alterations are frequent in patients with cancer, and strongly impact prognosis and survival. The development of cancers in immunosuppressed patients has demonstrated the contribution o...

    Authors: Christine Ménétrier-Caux, Isabelle Ray-Coquard, Jean-Yves Blay and Christophe Caux

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:85

    Content type: Review

    Published on:

  18. Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerg...

    Authors: Junaid Raja, Johannes M. Ludwig, Scott N. Gettinger, Kurt A. Schalper and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:140

    Content type: Review

    Published on:

  19. Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with h...

    Authors: Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June and Michael R. Bishop

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:137

    Content type: Review

    Published on:

  20. Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inh...

    Authors: Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone II, Joe Y. Chang, James W. Welsh and Charles R. Thomas Jr

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:128

    Content type: Review

    Published on:

  21. The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over...

    Authors: Maartje W. Rohaan, Joost H. van den Berg, Pia Kvistborg and John B. A. G. Haanen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:102

    Content type: Review

    Published on:

  22. CD8+ T lymphocytes are the major anti-tumor effector cells. Most cancer immunotherapeutic approaches seek to amplify cytotoxic T lymphocytes (CTL) specific to malignant cells. A recently identified subpopulation ...

    Authors: Fathia Mami-Chouaib, Charlotte Blanc, Stéphanie Corgnac, Sophie Hans, Ines Malenica, Clémence Granier, Isabelle Tihy and Eric Tartour

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:87

    Content type: Review

    Published on:

  23. Cancer surgery is necessary and life-saving. However, the majority of patients develop postoperative recurrence and metastasis, which are the main causes of cancer-related deaths. The postoperative stress resp...

    Authors: Orneala Bakos, Christine Lawson, Samuel Rouleau and Lee-Hwa Tai

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:86

    Content type: Review

    Published on:

  24. Recent advances in our understanding of the dynamics of cellular cross-talk have highlighted the significance of host-versus-tumor effect that can be harnessed with immune therapies. Tumors exploit immune chec...

    Authors: Muhammad Umair Mushtaq, Athanasios Papadas, Adam Pagenkopf, Evan Flietner, Zachary Morrow, Sibgha Gull Chaudhary and Fotis Asimakopoulos

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:65

    Content type: Review

    Published on:

  25. During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific ...

    Authors: Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll and Michael S. von Bergwelt-Baildon

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:56

    Content type: Review

    Published on:

  26. Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to ...

    Authors: Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar and Richard Tuli

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:46

    Content type: Review

    Published on:

  27. Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (F...

    Authors: Young Kwang Chae, Ayush Arya, Wade Iams, Marcelo R. Cruz, Sunandana Chandra, Jaehyuk Choi and Francis Giles

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:39

    Content type: Review

    Published on:

  28. Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and bio...

    Authors: Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George and Tian Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:4

    Content type: Review

    Published on:

  29. Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for...

    Authors: David H. Aggen and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:94

    Content type: Review

    Published on:

  30. With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic optio...

    Authors: Adam Ajina and John Maher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:90

    Content type: Review

    Published on:

  31. Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-maligna...

    Authors: Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon and Willem W. Overwijk

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:79

    Content type: Review

    Published on:

  32. The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particula...

    Authors: Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:78

    Content type: Review

    Published on:

  33. Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Soc...

    Authors: Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:77

    Content type: Meeting report

    Published on:

  34. Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs and a growing list of approved immune-based agents across a variety of disease states. Despite the early succe...

    Authors: James L. Gulley, Elizabeth A. Repasky, Laura S. Wood and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:55

    Content type: Review

    Published on:

  35. The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 ...

    Authors: Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries and Dominik Rüttinger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:53

    Content type: Review

    Published on:

  36. This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November...

    Authors: Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky Jr., Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:50

    Content type: Review

    Published on:

  37. As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic...

    Authors: Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:44

    Content type: Review

    Published on:

  38. Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...

    Authors: David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri and Barbara Seliger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:21

    Content type: Review

    Published on:

  39. Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...

    Authors: Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:16

    Content type: Review

    Published on:

  40. Established tumors build a stressful and hostile microenvironment that blocks the development of protective innate and adaptive immune responses. Different subsets of immunoregulatory myeloid populations, incl...

    Authors: Juan R. Cubillos-Ruiz, Eslam Mohamed and Paulo C. Rodriguez

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:5

    Content type: Review

    Published on:

  41. Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populatio...

    Authors: Jiwon S. Park, Sita S. Withers, Jaime F. Modiano, Michael S. Kent, Mingyi Chen, Jesus I. Luna, William T. N. Culp, Ellen E. Sparger, Robert B. Rebhun, Arta M. Monjazeb, William J. Murphy and Robert J. Canter

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:97

    Content type: Review

    Published on:

  42. Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolo...

    Authors: Hiep Khong and Willem W. Overwijk

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:56

    Content type: Review

    Published on:

Annual Journal Metrics

Advertisement